defa14a
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(Rule 14a-101)
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
Filed by the Registrant þ
Filed by a Party other than the Registrant o
Check appropriate box:
o |
|
Preliminary Proxy Statement |
o |
|
Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
o |
|
Definitive Proxy Statement |
o |
|
Definitive Additional Materials |
þ |
|
Soliciting Material pursuant to § 240.14a-12 |
VALEANT PHARMACEUTICALS INTERNATIONAL
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)
Payment of filing fee (Check the appropriate box):
þ |
|
No fee required. |
o |
|
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
|
(1) |
|
Title of each class of securities to which transaction applies:
|
|
|
(2) |
|
Aggregate number of securities to which transaction applies:
|
|
|
(3) |
|
Per unit price or other underlying value of transaction computed pursuant to Exchange
Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it
was determined):
|
|
|
(4) |
|
Proposed maximum aggregate value of transaction:
|
|
|
(5) |
|
Total fee paid:
|
o |
|
Fee paid previously with preliminary materials. |
|
o |
|
Check box if any part of the fee is offset as provided by Exchange
Act Rule 0-11(a)(2) and identify the filing for which the
offsetting fee was paid previously. Identify the previous filing
by registration statement number, or the form or schedule and the
date of its filing. |
|
(1) |
|
Amount Previously Paid:
|
|
|
(2) |
|
Form, Schedule or Registration Statement No.:
|
|
|
(3) |
|
Filing Party:
|
|
|
(4) |
|
Date Filed:
|
EXPLANATORY NOTE
The following is a copy of a communication sent by Valeant Pharmaceuticals International
(Valeant) to employees in the U.S. and Canada on June 21, 2010 relating to the Agreement and Plan
of Merger, dated as of June 20, 2010, among Valeant, Biovail Corporation, Biovail Americas Corp.
and Beach Merger Corp.
June 21, 2010
Dear Colleagues,
I am pleased to share some exciting news with you. Earlier today, Valeant and Biovail announced
that their Boards of Directors have unanimously approved a definitive merger agreement to combine
the companies. The combined company will be called Valeant Pharmaceuticals International, Inc.
(the new Valeant). We believe the new Valeants scale, financial strength and complementary
product lines will enable it to pursue substantial growth opportunities.
The new Valeant will have a significantly expanded presence in North America and operations in
eight other countries, working across four growth platforms. The combined company will be able to
leverage its complementary product lines and operations in specialty Central Nervous System (CNS),
Dermatology, Canada and emerging markets/branded generics. In addition, the combined company will
have limited patent exposure and enjoy strong and stable cash flows from legacy products that will
support future growth. The new Valeant, on a 12-month trailing basis, would have experienced
double digit revenue growth. Bringing together Valeant and Biovail will create greater
opportunities for both companies at a level that would not have been possible for either on a
stand-alone basis.
Biovail is a specialty pharmaceutical company engaged in the formulation, clinical testing,
registration, manufacture, and commercialization of pharmaceutical products. With approximately
1,300 employees worldwide, Biovail is Canadas largest publicly traded pharmaceutical company and
is headquartered in Mississauga, Ontario. The Company is focused on the development and
commercialization of medicines that address unmet medical needs in niche specialty Central Nervous
System (CNS) markets.
As you know, we at Valeant have been paving the way for growth through steadfast execution of our
strategic plan, which focuses on a diversified product portfolio and geographic footprint. We have
consistently pursued unique opportunities to grow our business and to build a strong and growing
pharmaceutical company that can respond to and take advantage of changes in our industry.
The combination with Biovail accelerates the achievement of our strategic goals many times over.
Just as we have done over the past two years, we will transform the new Valeant and apply our
strategy and operating philosophy to the combined companys portfolio, building on our track record
to create long-term value for all our stakeholders, from our partners, employees, and investors to
the patients who depend on our products. As we take the next step in our transformation, we will
be setting the bar, and our stretch goals, even higher.
Impact on Employees
As the new Valeant, we will have the opportunity to execute our strategy and mission on a larger
scale, and to take advantage of the key capabilities and talent that Biovail brings to the table.
Given that we have operations in many countries that Biovail does not, for the vast majority of our
employees, it will be business as usual. Those employees who could see a change are most likely to
be those in Canada and in our U.S. operations.
Both companies have grown by double-digits in Canada and, once combined, we will be the largest
pharmaceuticals company located in Canada and owned by a Canadian parent company.
Following completion of the merger, the combined company will be headquartered in Mississauga,
Ontario. In addition, the new Valeant will retain Biovails existing principal operating
subsidiary in Barbados, which will continue to own, manage, control and develop intellectual
property for the combined company. The location of the new Valeants U.S. headquarters will be
determined after the close of the transaction.
With respect to both our presence in Canada and the U.S. headquarters, at this juncture it is
important to remember that this transaction is about growth and with that there will be good jobs
for good people.
The combined companys Board of Directors will be comprised of individuals from both Valeant and
Biovail. I will become the new Valeants Chief Executive Officer, residing in Barbados, and Bill
Wells, currently Chief Executive Officer of Biovail, will serve as non-executive Chairman. We will
be forming a team comprised of senior executives from both companies, reporting to me, to assist
with the transition process.
Enhanced Offerings
By harnessing the strengths of both companies, we will be well-positioned to further deliver on our
shared goal of developing innovative solutions that provide meaningful benefits to patients with
special medical needs to help improve their quality of life. Our respective companies each have a
diverse product portfolio and pipeline, with a demonstrated ability to unlock hidden value in
overlooked assets. Our complementary efforts will expand our already strong franchises, and
together, we will have a product pipeline with greater depth and scope and more efficient
commercialization pathways through which to bring products to market.
Generates Value for Stockholders
Under the terms of the agreement, Valeant stockholders including those of you who hold stock
will receive a one-time special dividend of $16.77 per share prior to closing of the merger and
1.7809 shares of Biovail common stock upon closing of the merger in exchange for each share of
Valeant common stock they own. It is anticipated that by December 31, 2010, contingent upon the
closing of the merger and subject to approval by the combined companys Board of Directors and to
applicable law, the new Valeant will pay a one-time $1.00 per share dividend to all stockholders of
the combined entity. Upon the completion of the merger, Biovail stockholders will own
approximately 50.5 percent and Valeant stockholders will own approximately 49.5 percent of the
shares of the combined company` on a fully diluted basis.
What to Expect Next
The merger is expected to be complete before the end of the year. In terms of next steps, it is
important to understand that until the transaction closes, Valeant and Biovail will continue to
operate as independent companies and it will be business as usual here at Valeant. Both Valeant
and Biovail have track records of successful integrations, and I am confident that this transaction
will be completed seamlessly.
Members of our executive team will be visiting our various sites and will be on hand to answer
questions and concerns. Further, there are two opportunities today to learn more about this
combination and what it means to you. We will host a conference call and a live Internet webcast
along with a slide presentation today at 8:30 a.m. EDT (5:30 a.m. PDT) to discuss this combination.
The dial-in number to participate on this call is (877) 295-5743, confirmation code
83365938. International callers should dial (973) 200-3961, confirmation code 83365938. A replay
will be available for one week following the live webcast through June 28, 2010. The live webcast
of the conference call may be accessed through the investor relations section on Valeants web site
at www.valeant.com and Biovails web site at www.biovail.com.
I also hope you will join Bill and me for an all-employee webcast today at 3:30 pm ET. You can
access the webcast at http://206.47.0.157/console/console-login?active=yes or to
participate via telephone dial-in
(416) 340-2217 / (866)-696-5910, confirmation code 4064295. You
can email your questions in advance to corp. communications@valeant.com or follow the operators
instructions to ask questions on the call. Well work to address as many questions as we can.
A copy of the press release we issued this morning, as well as an FAQ answering some of the
questions you may have, are attached to this email. As we move forward, well do our very best to
keep you informed in a timely manner.
It is likely that todays news will lead to increased interest in Valeant, and it is important we
speak with one voice on this matter. If you receive any inquiries from the media or other
interested parties, please refer them to Laurie Little at 949-461-6002 (or
laurie.little@Valeant.com).
We owe much of our success to your tireless efforts and this attitude continues to drive us to
generate long-term value and success. As we move through this process, well continue to rely on
you to stay focused on the work at hand, serve our partners and patients, and help achieve our
goals.
Thank you for all you do to make our company successful.
Sincerely,
Michael Pearson
Chairman and Chief Executive Officer
Caution Regarding Forward-Looking Information and Safe Harbor Statement
To the extent any statements made in this document contain information that is not historical,
these statements are forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and
may be forward-looking information as defined under applicable Canadian securities legislation
(collectively, forward-looking statements).
These forward-looking statements relate to, among other things, the expected benefits of the
proposed merger such as efficiencies, cost savings, tax benefits, enhanced revenues and cash flow,
growth potential, market profile and financial strength; the competitive ability and position of
the combined company; the expected timing of the completion of the transaction; and the expected
payment of a one-time cash dividend. Forward-looking statements can generally be identified by the
use of words such as believe, anticipate, expect, estimate, intend, continue, plan,
project, will, may, should, could, would, target, potential and other similar
expressions. In addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking statements. Although
certain of these statements set out herein are indicated above, all of the statements in this
letter that contain forward-looking statements are qualified by these cautionary statements.
Although Valeant and Biovail believe that the expectations reflected in such forward-looking
statements are reasonable, such statements involve risks and uncertainties, and undue reliance
should not be placed on such statements. Certain material factors or assumptions are applied in
making forward-looking statements, including, but not limited to, factors and assumptions regarding
the items outlined above. Actual results may differ materially from those expressed or implied in
such statements. Important factors that could cause actual results to differ materially from these
expectations include, among other things, the following: the failure to receive, on a timely basis
or otherwise, the required approvals by Valeant and Biovail stockholders and government or
regulatory agencies (including the terms of such approvals); the risk that a condition to closing
of the merger may not be satisfied; the possibility that the anticipated benefits and synergies
from the proposed merger cannot be fully realized or may take longer to realize than expected; the
possibility that costs or difficulties related to the integration of Valeant and Biovail operations
will be greater than expected; the ability of the combined company to retain and hire key personnel
and maintain relationships with customers, suppliers or other business partners; the impact of
legislative, regulatory, competitive and technological changes; the risk that the credit ratings of
the combined company may be different from what the companies expect; and other risk factors
relating to the pharmaceutical industry, as detailed from time to time in each of Valeants and
Biovails reports filed with the Securities and Exchange Commission (SEC) and, in Biovails case,
the Canadian Securities Administrators (CSA). There can be no assurance that the proposed merger
will in fact be consummated.
Additional information about these factors and about the material factors or assumptions underlying
such forward-looking statements may be found in the body of this letter, as well as under Item 1.A.
in each of Valeants and Biovails Annual Report on Form 10-K for the fiscal year ended December
31, 2009, and Item 1.A in each of Valeants and Biovails most recent Quarterly Report on Form 10-Q
for the quarterly period ended March 31, 2010. Valeant and Biovail caution that the foregoing list
of important factors that may affect future results is not exhaustive. When relying on
forward-looking statements to make decisions with respect to Valeant and Biovail, investors and
others should carefully consider the foregoing factors and other uncertainties and potential
events. Neither Biovail nor Valeant undertakes any obligation to update or revise any
forward-looking statement, except as may be required by law.
Additional Information
In connection with the proposed merger, Valeant and Biovail plan to file with the SEC a
Registration Statement on Form S-4 that will include a joint proxy statement of Valeant and Biovail
that also constitutes a prospectus of each of Valeant and Biovail. Valeant and Biovail will mail
the joint proxy statement/prospectus to their respective stockholders. INVESTORS ARE URGED TO READ
THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT
INFORMATION. You will be able to obtain the joint proxy statement/prospectus, as well as other
filings containing information about Valeant and Biovail, free of charge, at the website maintained
by the SEC at www.sec.gov and, in Biovails case, on SEDAR at www.sedar.com. You may also obtain
these documents, free of charge, from Valeants website (www.valeant.com) under the tab Investor
Relations and then under the heading SEC Filings, or by directing a request to Valeant, One
Enterprise, Aliso Viejo, California, 92656, Attention: Corporate Secretary. You may also obtain
these documents, free of charge, from Biovails website (www.biovail.com) under the tab Investor
Relations and then under the heading Regulatory Filings and then under the item Current SEC
Filings, or by directing a request to Biovail, 7150 Mississauga Road, Mississauga, Ontario,
Canada, L5N 8M5, Attention: Corporate Secretary.
The respective directors and executive officers of Valeant and Biovail and other persons may be
deemed to be participants in the solicitation of proxies in respect of the proposed transaction.
Information regarding Valeants directors and executive officers is available in its definitive
proxy statement filed with the SEC by Valeant on March 25, 2010, and information regarding Biovail
directors and executive officers is available in its definitive proxy statement filed with the SEC
and CSA by Biovail on April 21, 2010. These documents can be obtained free of charge from the
sources indicated above. Other information regarding the interests of the participants in the
proxy solicitation will be included in the joint proxy statement/prospectus and other relevant
materials to be filed with the SEC and the CSA when they become available. This communication
shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation
of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. No offer of securities shall be made except by
means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as
amended.
Valeant Employee FAQ
1. |
|
What was announced today? |
Valeant and Biovail today announced that both companies boards of directors have unanimously
approved a definitive merger agreement to combine the companies. The combined company will be
called Valeant Pharmaceuticals International, Inc. (the new Valeant).
Biovail is a specialty pharmaceutical company engaged in the formulation, clinical testing,
registration, manufacture, and commercialization of pharmaceutical products. With approximately
1,300 employees worldwide, Biovail is Canadas largest publicly traded pharmaceutical company and
is headquartered in Mississauga, Ontario. The Company is focused
on the development and commercialization of medicines that address unmet medical needs in niche
specialty Central Nervous System (CNS) markets.
3. |
|
Why are Valeant and Biovail combining? |
The combination of Valeant and Biovail creates a new leader in specialty pharmaceuticals that will
be able to create opportunities for both companies at a level that would not have been possible for
either on a stand-alone basis.
The new Valeant will have a significantly expanded presence in North America and operations in
eight other countries, working across four growth platforms. The new Valeant will be able to
leverage its complementary product lines and operations in specialty CNS, Dermatology, Canada and
emerging markets/branded generics. In addition, the combined company will have limited patent
exposure and enjoy strong and stable cash flows from legacy products that will support future
growth. The new Valeant, on a 12-month trailing basis as of March 31, 2010, would have experienced
double digit revenue growth.
4. |
|
How will this transaction benefit employees? |
As a result of this merger, our employees will have the opportunity to execute our strategy and
mission on a larger scale and to take advantage of the key capabilities and talent that this
combination will bring.
5. |
|
Who will lead the new Valeant? |
Following the close of the transaction, Mike Pearson will serve as the new Valeants Chief
Executive Officer, residing in Barbados and Bill Wells, currently Chief Executive Officer of
Biovail, will be the non-executive Chairman.
The combined companys Board of Directors will consist of eleven members, including five Biovail
representatives, five Valeant representatives and an additional independent Canadian resident
director to be identified through a search process and nominated by Valeant and agreed upon by
Biovail. Robert A. Ingram, currently lead director of Valeant, will serve as lead independent
director of the combined Board. Michael Van Every, currently Chairman of Biovails Audit
Committee, will serve in the same function for the combined Board.
6. |
|
What are the plans to integrate us with Biovail? |
A team comprised of senior executives from both companies will be formed to assist with the
transition process. Both companies have successful integration track records, and we are confident
that this transaction will be completed seamlessly.
7. |
|
I own shares in Valeant. What does this mean to me? |
Under the terms of the agreement, Valeant stockholders including those of you who hold stock
will receive a one-time special dividend of $16.77 per share prior to closing of the merger and
1.7809 shares of Biovail common stock upon closing of the merger in exchange for each share of
Valeant common stock they own. It is anticipated that by December 31, 2010, contingent upon
the closing of the merger and subject to approval by the combined companys Board of Directors and
to applicable law, the new Valeant will pay a one-time $1.00 per share dividend to all stockholders
of the combined entity. Upon the completion of the merger, Biovail stockholders will own
approximately 50.5 percent and Valeant stockholders will own approximately 49.5 percent of the
shares of the new Valeant on a fully diluted basis.
8. |
|
Will salaries and benefits be affected? Will my 401k or health care benefits change? |
The combining of our companies will involve an integration process that will take many months.
Determining benefits for employees will be a part of that integration process, and we will promptly
communicate any changes when the process is complete and final decisions are made. As always, if
you have questions about your benefits, please contact your HR representative.
9. |
|
Will there be any layoffs because of this merger? |
The new organization will give us an opportunity to execute our strategy and mission on a larger
scale, and to take advantage of the key capabilities and talent that Biovail brings to the table.
Given that we have operations in many countries that Biovail does not, for the vast majority of our
employees, it will be business as usual. However, as in any combination of two companies in the
same industry, there will be some overlap and therefore job reductions. Those employees who could
see a change are most likely to be those in Canada and in our U.S. operations. At this juncture it
is important to remember that this transaction is about growth. We will communicate new
information when it becomes available and will provide answers to questions as soon as decisions
are made.
10. |
|
What will happen to our headquarters in Aliso Viejo, CA? |
Following completion of the merger, the new Valeant will be headquartered in Mississauga, Ontario.
In addition, we will retain Biovails existing principal operating subsidiary in Barbados, which
will continue to own, manage, control and develop intellectual property for the combined company.
The location of our U.S. headquarters will be determined after the close of the transaction.
11. |
|
What can you tell me about decisions to close plants or R&D sites? |
At this time, its premature to discuss any specific plans. A team comprised of senior executives
from both companies will be formed to assist with the transition process. We will communicate new
information when it becomes available and will provide answers to questions as soon as decisions
are made.
12. |
|
How long before the merger is completed? |
We intend to move forward expeditiously so that we can begin to capture the benefits of this
transaction quickly. We anticipate the transaction to be completed before the end of the year.
13. |
|
What can we expect in the interim before the transaction closes? |
Valeant and Biovail will continue to operate as independent companies until the transaction closes,
and we expect that between now and then, the day-to-day operations of each company will continue
normally. We owe much of our success to your tireless efforts. As we move through
this process, well continue to rely on you to focus on the work at hand, serve our partners and
patients, and help achieve our goals.
14. |
|
What should I say if Im contacted by media, financial community, or other third parties
about the transaction? |
It is likely that todays news will lead to increased interest in Valeant, and it is important we
speak with one voice on this matter. If you receive any inquiries from the media or other
interested parties, please refer them to Laurie Little at 949-461-6002 (or
laurie.little@Valeant.com).
15. |
|
How will I know more about the progress of the transaction? |
We recognize that this transaction impacts you, and we plan to update you regularly. We appreciate
that each company has a culture of remaining focused on the challenges of our competitive business,
and we thank you in advance for that continued focus in the months ahead.
In the coming days and weeks, members of our respective executive teams will be visiting our
various sites and will be on hand to answer questions and concerns.
Caution Regarding Forward-Looking Information and Safe Harbor Statement
To the extent any statements made in this document contain information that is not historical,
these statements are forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and
may be forward-looking information as defined under applicable Canadian securities legislation
(collectively, forward-looking statements).
These forward-looking statements relate to, among other things, the expected benefits of the
proposed merger such as efficiencies, cost savings, tax benefits, enhanced revenues and cash flow,
growth potential, market profile and financial strength; the competitive ability and position of
the combined company; the expected timing of the completion of the transaction; and the expected
payment of a one-time cash dividend. Forward-looking statements can generally be identified by the
use of words such as believe, anticipate, expect, estimate, intend, continue, plan,
project, will, may, should, could, would, target, potential and other similar
expressions. In addition, any statements that refer to expectations, projections or other
characterizations of future events or circumstances are forward-looking statements. Although
certain of these statements set out herein are indicated above, all of the statements in this
letter that contain forward-looking statements are qualified by these cautionary statements.
Although Valeant and Biovail believe that the expectations reflected in such forward-looking
statements are reasonable, such statements involve risks and uncertainties, and undue reliance
should not be placed on such statements. Certain material factors or assumptions are applied in
making forward-looking statements, including, but not limited to, factors and assumptions regarding
the items outlined above. Actual results may differ materially from those expressed or implied in
such statements. Important factors that could cause actual results to differ materially from these
expectations include, among other things, the following: the failure to receive, on a timely basis
or otherwise, the required approvals by Valeant and Biovail stockholders and government or
regulatory agencies (including the terms of such approvals); the risk that a condition to closing
of the merger may not be satisfied; the possibility that the anticipated benefits and synergies
from the proposed merger cannot be fully realized or may take longer to realize than expected; the
possibility that costs or difficulties related to the integration of Valeant and Biovail operations
will be greater than expected; the ability of the combined company to retain and hire key personnel
and maintain relationships with customers, suppliers or other business partners; the impact of
legislative, regulatory, competitive and technological changes; the risk that the credit ratings of
the combined company may be different from what the companies expect; and other risk factors
relating to the pharmaceutical industry, as detailed from time to time in each of Valeants and
Biovails reports filed with the Securities and Exchange Commission (SEC) and, in Biovails case,
the Canadian Securities Administrators (CSA). There can be no assurance that the proposed merger
will in fact be consummated.
Additional information about these factors and about the material factors or assumptions underlying
such forward-looking statements may be found in the body of this letter, as well as under Item 1.A.
in each of Valeants and Biovails Annual Report on Form 10-K for the fiscal year ended December
31, 2009, and Item 1.A in each of Valeants and Biovails most recent Quarterly Report on Form 10-Q
for the quarterly period ended March 31, 2010. Valeant and Biovail caution that the foregoing list
of important factors that may affect future results is not exhaustive. When relying on
forward-looking statements to make decisions with respect to Valeant and Biovail, investors and
others should carefully consider the foregoing factors and other uncertainties and potential
events. Neither Biovail nor Valeant undertakes any obligation to update or revise any
forward-looking statement, except as may be required by law.
Additional Information
In connection with the proposed merger, Valeant and Biovail plan to file with the SEC a
Registration Statement on Form S-4 that will include a joint proxy statement of Valeant and Biovail
that also constitutes a prospectus of each of Valeant and Biovail. Valeant and Biovail will mail
the joint proxy statement/prospectus to their respective stockholders. INVESTORS ARE URGED TO READ
THE JOINT PROXY STATEMENT/PROSPECTUS WHEN IT BECOMES AVAILABLE BECAUSE IT WILL CONTAIN IMPORTANT
INFORMATION. You will be able to obtain the joint proxy statement/prospectus, as well as other
filings containing information about Valeant and Biovail, free of charge, at the website maintained
by the SEC at www.sec.gov and, in Biovails case, on SEDAR at www.sedar.com. You may also obtain
these documents, free of charge, from Valeants website (www.valeant.com) under the tab Investor
Relations and then under the heading SEC Filings, or by directing a request to Valeant, One
Enterprise, Aliso Viejo, California, 92656, Attention: Corporate Secretary. You may also obtain
these documents, free of charge, from Biovails website (www.biovail.com) under the tab Investor
Relations and then under the heading Regulatory Filings and then under the item Current SEC
Filings, or by directing a request to Biovail, 7150 Mississauga Road, Mississauga, Ontario,
Canada, L5N 8M5, Attention: Corporate Secretary.
The respective directors and executive officers of Valeant and Biovail and other persons may be
deemed to be participants in the solicitation of proxies in respect of the proposed transaction.
Information regarding Valeants directors and executive officers is available in its definitive
proxy statement filed with the SEC by Valeant on March 25, 2010, and information regarding Biovail
directors and executive officers is available in its definitive proxy statement filed with the SEC
and CSA by Biovail on April 21, 2010. These documents can be obtained free of charge from the
sources indicated above. Other information regarding the interests of the participants in the
proxy solicitation will be included in the joint proxy statement/prospectus and other relevant
materials to be filed with the SEC and the CSA when they become available. This communication
shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation
of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in
which such offer, solicitation or sale would be unlawful prior to registration or qualification
under the securities laws of any such jurisdiction. No offer of securities shall be made except by
means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as
amended.